CCR4 and neoplasm: CCR4 has been validated as a CAR-T target as Perera and colleagues have demonstrated the ability of an anti-CCR4-CAR to lyse multiple T-cell lines in vitro and clear T-ALL tumor in a xenograft mouse model (18).